Supported by three innovative drug discovery platforms we aim to design new solutions for poorly managed diseases, like cancer, autoimmune conditions or Central Nervous System (CNS) diseases.
Our technology platforms are set up to provide new, highly competitive, „best in class” or „first in class” new medicines to improve or extend the life of millions of people.
The starting point of our solution is animal toxins. Molecular targets of toxins play a critical role in essential life functions, and as such in the treatment of many diseases the same molecular targets can provide a starting point for drug discovery. We are developing new drugs based on animal toxins across indications.
The “Designer miniprotein” technology platform, based on naturally occurring toxins and other peptide molecules, creates a peptide megalibrary with more than a million variants. From the identified peptide analogues, the most promising drug candidates can be selected on the basis of desired pharmacological properties.
In our laboratories at VRG, all experimental methods for testing candidate peptide/protein molecules are available. Besides commercially available approaches, several methods have been developed in house to test the newly created peptides for their pharmacological and biological properties such as binding strength, inhibitory or stimulatory effect on target proteins involved in selected diseases.